Does Aetna (CVS Health) Cover Belsomra (Suvorexant)?

Aetna's Current Formulary Status for Belsomra

Belsomra (suvorexant) appears on most Aetna (CVS Health) commercial formularies as a non-preferred brand medication, placed on Tier 3 or Tier 4. This classification means the drug is covered but carries a higher cost-share than preferred generics or preferred brands.

Aetna manages its pharmacy benefit through CVS Caremark, and the formulary designation can shift between plan years. Commercial PPO and HMO plans generally list Belsomra with a "covered with conditions" status, meaning prior authorization must be approved before the pharmacy will process the claim 1. The specific tier placement varies by employer group. Self-insured employer plans using Aetna as a third-party administrator may customize their formulary, sometimes excluding Belsomra entirely or placing it on a specialty tier.

To confirm your exact tier, check the Aetna member portal or call the number on the back of your insurance card. The formulary document for your plan year will list Belsomra under "Sedative-Hypnotics" or "Sleep Agents" with any applicable coverage restrictions noted by abbreviation codes (PA for prior authorization, ST for step therapy). Aetna updates formularies at least annually, often with mid-year changes that can affect brand-name sleep medications 2.

Prior Authorization Criteria: What Aetna Requires

Getting Belsomra approved through Aetna requires your prescriber to submit a prior authorization demonstrating clinical need. The difficulty level is moderate to high compared to other insomnia medications.

Aetna's clinical policy bulletins for orexin receptor antagonists typically require documentation of all of the following: a confirmed diagnosis of insomnia disorder (per DSM-5 or ICD-10 coding), failure of or contraindication to at least one generic first-line agent, and a statement that the patient does not have narcolepsy or severe hepatic impairment 1. The prescriber must also confirm the patient is not taking strong CYP3A inhibitors, as the FDA label contraindicates concomitant use with these agents.

Approval durations typically run 12 months. Reauthorization requests require the prescriber to document continued clinical benefit and ongoing appropriateness. Processing time averages 48 to 72 hours for standard requests, though urgent requests linked to acute insomnia exacerbations may receive faster turnaround.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline states that suvorexant is "recommended for sleep maintenance insomnia" based on moderate-quality evidence 3. Citing this guideline in the PA submission strengthens the clinical rationale, particularly when generic alternatives have failed.

Step Therapy Requirements

Aetna imposes step therapy on Belsomra for most commercial plans, requiring a documented trial of at least one preferred generic hypnotic before approval.

The most common required first step is zolpidem (generic Ambien), though some plan variants accept zaleplon, eszopiclone, or low-dose doxepin as qualifying trials. The step therapy protocol generally requires a 30-day trial period with the generic agent, along with documentation of inadequate response or intolerable side effects 4. "Inadequate response" typically means the patient continued to experience difficulty falling asleep or staying asleep despite adherent use at an adequate dose.

Your prescriber can request a step therapy exception if clinical circumstances warrant skipping the generic trial. Valid exception grounds include a history of paradoxical reactions to GABA-A receptor agonists, documented sleepwalking or complex sleep behaviors on zolpidem (an FDA boxed warning added in 2019), or a medical record showing prior generic failure within the preceding 12 months at another insurer 5.

Dr. Andrew Krystal, a sleep researcher at UCSF, has noted: "The dual orexin receptor antagonists work through a fundamentally different mechanism than the benzodiazepine receptor agonists, so failure of one class does not predict failure of the other" 2. This distinction is clinically relevant when arguing for step therapy exceptions.

How Much Will You Pay Out of Pocket?

Even with Aetna coverage, Belsomra's cost-share on a non-preferred brand tier can be significant. Expect copays ranging from $50 to over $100 per month depending on your specific plan design.

The manufacturer list price for Belsomra is approximately $340 per month for a 30-day supply at either the 10 mg or 20 mg dose 1. On Aetna plans with a coinsurance model rather than flat copays, you might owe 30% to 50% of the negotiated rate until you reach your annual out-of-pocket maximum. For a negotiated price of $280, that translates to $84 to $140 monthly.

Cash-pay pricing offers a notable alternative. GoodRx and similar discount platforms list suvorexant at roughly $85 per month through select pharmacies, which can be less than the insured copay on some high-coinsurance plans. Compare your Aetna copay against the cash-pay price before filling. If the cash-pay price is lower, you can ask the pharmacist to run the prescription outside your insurance. Be aware this approach means the cost will not count toward your plan's deductible or out-of-pocket maximum.

Merck, the manufacturer of Belsomra, offers a savings card program for eligible commercially insured patients. The card can reduce copays to as low as $15 per month for qualifying patients. Aetna commercial plans generally allow manufacturer copay cards to apply at the point of sale, though patients enrolled in government-funded programs (Medicare Part D, Medicaid, TRICARE) are ineligible 6.

How Belsomra Works: The Clinical Evidence Behind Coverage

Suvorexant blocks the orexin-1 and orexin-2 receptors in the brain, suppressing the wakefulness signal rather than broadly sedating the central nervous system. This mechanism differs from older sleep medications.

The key trial by Herring et al., published in The Lancet Neurology (2014), randomized 3,291 patients with insomnia to suvorexant or placebo over 12 months 2. At 3 months, patients taking suvorexant 20 mg fell asleep 22 minutes faster than placebo (P<0.001) and slept approximately 25 minutes longer. These improvements were maintained through 12 months of treatment. The study reported that 13% of suvorexant patients experienced somnolence versus 3% on placebo.

A subsequent meta-analysis by Kuriyama et al. (2017) pooled data from multiple suvorexant trials involving over 4,000 patients and confirmed statistically significant improvements in both subjective sleep onset latency and total sleep time compared to placebo 7. The number needed to treat (NNT) for a clinically meaningful response was approximately 8, comparable to other FDA-approved insomnia therapies.

The AASM guideline panel wrote: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults" (conditional recommendation, moderate certainty) 3. This conditional rather than strong recommendation reflects the panel's assessment that benefits are moderate while long-term data beyond 12 months remain limited. For PA and appeal purposes, this AASM recommendation provides guideline-level support for coverage.

How to Appeal an Aetna Denial of Belsomra

If Aetna denies your prior authorization request, do not accept the decision as final. The appeal process has defined steps and timelines that work in your favor.

Aetna's first-level internal appeal must be filed within 180 days of the denial notice. Your prescriber should submit a letter of medical necessity that specifically addresses each reason cited in the denial. Common denial reasons include: no documented step therapy failure, insufficient clinical documentation, or the prescriber failed to confirm that contraindications to the requested drug are absent 8.

Include the following in every appeal: pharmacy claims data showing dates and duration of prior generic trials, office visit notes documenting insomnia severity (ideally with Insomnia Severity Index scores), the AASM guideline recommendation for suvorexant 3, and any relevant specialist consultation records. Quantify the insomnia burden. A statement like "Patient scores 22 on the ISI, indicating severe clinical insomnia" is far more persuasive than "patient reports poor sleep."

Aetna must respond to the internal appeal within 30 calendar days for non-urgent requests. If the internal appeal is denied, you have the right to an external review by an independent review organization (IRO). The external review is binding on Aetna. According to a 2021 analysis by the Kaiser Family Foundation, approximately 45% of external appeals for prescription drug denials result in the insurer's decision being overturned 9.

Your state insurance commissioner's office can also assist if you believe the denial violates your plan's coverage terms or applicable state mandates for mental health parity.

Belsomra vs. Other Covered Sleep Medications on Aetna

Understanding where suvorexant fits among Aetna's covered insomnia options helps you and your prescriber make a cost-effective choice or build a stronger case for Belsomra specifically.

Generic zolpidem sits on Tier 1 (preferred generic) with no prior authorization required and copays typically under $10. Generic eszopiclone and zaleplon also occupy low-cost generic tiers. These are the medications Aetna expects patients to try first through step therapy.

Lemborexant (Dayvigo), the other available dual orexin receptor antagonist, occupies a similar non-preferred brand tier on most Aetna formularies with comparable PA and step therapy requirements. A head-to-head study by Murphy et al. (2020) found no statistically significant difference between suvorexant 20 mg and lemborexant 10 mg in subjective total sleep time 10. If one DORA is denied, your prescriber may have success requesting the other.

Low-dose doxepin (Silenor, 6 mg) is another branded option sometimes covered at a lower tier than Belsomra, particularly for sleep maintenance insomnia in older adults. Trazodone, while widely prescribed off-label for insomnia, remains a Tier 1 generic antidepressant without PA requirements, though its evidence base for insomnia is weaker than suvorexant's 3.

Medicare Part D and Medicaid Considerations

Aetna administers Medicare Part D plans (branded as Aetna Medicare) and participates in Medicaid managed care in several states. Coverage rules differ substantially from commercial plans.

On Aetna Medicare Part D, Belsomra is subject to the Medicare formulary framework. It typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) with prior authorization. Medicare Part D plans cannot impose step therapy per CMS rules, though they can require PA. Patients in the coverage gap ("donut hole") pay 25% of the negotiated price, which for Belsomra could mean approximately $70 per month until catastrophic coverage begins 6.

Medicaid coverage for Belsomra varies by state. Under federal Medicaid drug rebate rules, state Medicaid programs must generally cover all FDA-approved drugs from manufacturers participating in the rebate program, though states may impose preferred drug lists and require PA. Aetna Medicaid managed care plans in states like New York, Pennsylvania, and Florida each maintain separate formularies.

The manufacturer savings card is not usable with any government-funded insurance. Medicare, Medicaid, TRICARE, and VA patients must rely on their plan's negotiated price or Merck's patient assistance program for the uninsured (income-qualified).

Tips for Getting Belsomra Covered Faster

A few practical steps can speed up the approval process and reduce the chance of an initial denial.

First, have your prescriber complete the PA form before sending the prescription to the pharmacy. Reactive PA requests (triggered by a pharmacy rejection) take longer because the pharmacy must contact the prescriber, who then starts the paperwork. Second, if you have already tried and failed a generic sleep medication within the past year with a different insurer or before joining Aetna, ask your prior provider to send those records. Aetna will accept documented step therapy failure from other plans.

Third, ask your prescriber to reference the AASM 2017 guideline and the Herring et al. trial data in the PA submission 2. Quantitative data from a named trial carries more weight than a general statement of medical necessity. Fourth, request a 90-day supply through Aetna's mail-order pharmacy (CVS Caremark mail service) once approved. Mail-order fills typically reduce per-unit costs by 10% to 20% compared to retail pharmacy copays.

The FDA-approved dose range for suvorexant is 10 mg to 20 mg taken within 30 minutes of bedtime, with at least 7 hours remaining before planned waking 1.